Literature DB >> 17302769

Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model.

Francisco Rentas1, Ronald Harman, Charlotte Gomez, Jeanne Salata, Joseph Childs, Tonya Silva, Lloyd Lippert, Joshua Montgomery, Allen Richards, Chye Chan, Ju Jiang, Heather Reddy, John Li, Raymond Goodrich.   

Abstract

BACKGROUND: Treatment of blood products with riboflavin and light has been used to reduce the number of certain pathogens. Orientia (formerly Rickettsia) tsutsugamushi, the scrub typhus agent, is an obligate intracellular bacterium that grows free in the cytoplasm of infected cells. This study evaluated the capability of riboflavin and light to inactivate O. tsutsugamushi in red blood cells (RBCs), platelets (PLTs), and plasma, as measured by mouse infectivity. STUDY DESIGN AND METHODS: A total of 108 mice, equally divided into groups receiving RBCs, plasma, and PLTs, received untreated products infected with 10(0) to 10(5) organisms. Eighteen mice received products infected with 10(5) organisms and were subsequently treated with riboflavin and light. Mice were monitored daily for up to 17 days for signs and symptoms of infection (e.g., lethargy, labored breathing, rough coat) and killed upon appearance of symptoms or on Day 17 after infection. Real-time polymerase chain reaction (PCR) on blood and Giemsa stains from peritoneal exudates were performed.
RESULTS: A total of 102 of 108 mice receiving the untreated products developed signs and symptoms of infection and had positive PCR and Giemsa stain results. None of the 18 animals receiving riboflavin and light-treated blood products exhibited signs or symptoms of infection, nor was infection observed by PCR testing or Giemsa staining.
CONCLUSIONS: Riboflavin and light are effective in reducing O. tsutsugamushi. Mice injected with blood products inoculated with 10(5) organisms and treated with riboflavin and light did not experience any signs or symptoms of infection, 17 days after inoculation. A 5-log reduction of this organism in blood was achieved as assayed in an animal model.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17302769     DOI: 10.1111/j.1537-2995.2007.01094.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

Authors:  Dragoslav Domanović; Ines Ushiro-Lumb; Veerle Compernolle; Sergio Brusin; Markus Funk; Pierre Gallian; Jørgen Georgsen; Mart Janssen; Teresa Jimenez-Marco; Folke Knutson; Giancarlo M Liumbruno; Polonca Mali; Giuseppe Marano; Yuyun Maryuningsih; Christoph Niederhauser; Constantina Politis; Simonetta Pupella; Guy Rautmann; Karmin Saadat; Imad Sandid; Ana P Sousa; Stefania Vaglio; Claudio Velati; Nicole Verdun; Miguel Vesga; Paolo Rebulla
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

2.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

3.  Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment.

Authors:  Rachael P Jackman; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2009-08-04       Impact factor: 3.157

4.  Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro.

Authors:  Andrew P Cap; Heather F Pidcoke; Shawn D Keil; Hilary M Staples; Manu Anantpadma; Ricardo Carrion; Robert A Davey; Ashley Frazer-Abel; Audra L Taylor; Richard Gonzales; Jean L Patterson; Raymond P Goodrich
Journal:  Transfusion       Date:  2016-03       Impact factor: 3.157

5.  [Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP].

Authors:  C Naegelen; H Isola; D Dernis; J-P Maurel; R Tardivel; S Bois; C Vignoli; J-P Cazenave
Journal:  Transfus Clin Biol       Date:  2009-05-13       Impact factor: 1.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.